BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21154521)

  • 1. Discounting and decision making in the economic evaluation of health-care technologies.
    Claxton K; Paulden M; Gravelle H; Brouwer W; Culyer AJ
    Health Econ; 2011 Jan; 20(1):2-15. PubMed ID: 21154521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.
    Schad M; John J
    Eur J Health Econ; 2012 Apr; 13(2):127-44. PubMed ID: 21170731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget allocation and the revealed social rate of time preference for health.
    Paulden M; Claxton K
    Health Econ; 2012 May; 21(5):612-8. PubMed ID: 21438069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discounting in health care decision-making: time for a change?
    Sheldon TA
    J Public Health Med; 1992 Sep; 14(3):250-6. PubMed ID: 1419202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments.
    Johnson FR; Backhouse M
    Value Health; 2006; 9(5):303-11. PubMed ID: 16961548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic assessment: a methodological primer.
    Simoens S
    Int J Environ Res Public Health; 2009 Dec; 6(12):2950-66. PubMed ID: 20049237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health economic decision-making: a comparison between UK and Spain.
    Corbacho B; Pinto-Prades JL
    Br Med Bull; 2012 Sep; 103(1):5-20. PubMed ID: 22833571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine.
    Paulden M; O'Mahony JF; McCabe C
    Pharmacoeconomics; 2017 Jan; 35(1):5-13. PubMed ID: 27943173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the usefulness of budget impact analyses: a U.S. payer perspective.
    Watkins JB; Danielson D
    Value Health; 2014; 17(1):3-4. PubMed ID: 24438711
    [No Abstract]   [Full Text] [Related]  

  • 14. On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
    Westra TA; Parouty M; Brouwer WB; Beutels PH; Rogoza RM; Rozenbaum MH; Daemen T; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2012 May; 15(3):562-7. PubMed ID: 22583467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.
    Sendi PP; Briggs AH
    Health Econ; 2001 Oct; 10(7):675-80. PubMed ID: 11747050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Unequal discounting of health care costs and effects causes confusion].
    van Ballegooijen M; de Kok IM; Habbema JD
    Ned Tijdschr Geneeskd; 2010; 154():A1970. PubMed ID: 20619050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discounting health effects in pharmacoeconomic evaluations: current controversies.
    Bos JM; Postma MJ; Annemans L
    Pharmacoeconomics; 2005; 23(7):639-49. PubMed ID: 16173156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential discounting in the economic evaluation of healthcare programs.
    John J; Koerber F; Schad M
    Cost Eff Resour Alloc; 2019; 17():29. PubMed ID: 31866768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.